Published in J Neurosci on May 04, 2017
Habits, rituals, and the evaluative brain. Annu Rev Neurosci (2008) 7.14
Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature (2001) 5.60
Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation. J Neurosci (1992) 5.37
HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci (2007) 3.73
Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav (1980) 3.69
Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization. Nat Neurosci (2010) 3.55
Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci (2008) 3.50
Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38
The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci (1992) 3.10
HIV dementia: an evolving disease. J Neuroimmunol (2004) 2.88
Dendritic spine dynamics. Annu Rev Physiol (2009) 2.66
D2R striatopallidal neurons inhibit both locomotor and drug reward processes. Nat Neurosci (2009) 2.65
Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci (2008) 2.29
Functional connectome of the striatal medium spiny neuron. J Neurosci (2011) 1.89
Differential excitability and modulation of striatal medium spiny neuron dendrites. J Neurosci (2008) 1.79
Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J Neurosci (2007) 1.73
HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat Rev Neurol (2016) 1.71
HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci U S A (2007) 1.71
Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci (2014) 1.66
Fine structure and synaptic connections of the common spiny neuron of the rat neostriatum: a study employing intracellular inject of horseradish peroxidase. J Comp Neurol (1980) 1.64
Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PLoS One (2009) 1.61
Parkinsonism with HIV infection. Mov Disord (1998) 1.58
Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol (2000) 1.53
Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology (2005) 1.51
Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons. Eur J Neurosci (2008) 1.49
Post-pubertal emergence of prefrontal cortical up states induced by D1-NMDA co-activation. Cereb Cortex (2004) 1.47
The structure of the caudate nucleus of the cat: light and electron microscopy. Philos Trans R Soc Lond B Biol Sci (1971) 1.45
Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia (2008) 1.42
Cocaine-induced adaptations in D1 and D2 accumbens projection neurons (a dichotomy not necessarily synonymous with direct and indirect pathways). Curr Opin Neurobiol (2013) 1.36
The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem (2010) 1.33
Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J Neurochem (1999) 1.32
Dopaminergic modulation of prefrontal cortical input to nucleus accumbens neurons in vivo. J Neurosci (2004) 1.29
HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther (2009) 1.28
Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. Brain Res (2000) 1.25
Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol (2010) 1.25
The ins and outs of HIV-1 Tat. Traffic (2011) 1.24
The dopamine d1-d2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in Basal Ganglia. Front Neuroanat (2011) 1.19
Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol (1997) 1.18
An Improved BAC Transgenic Fluorescent Reporter Line for Sensitive and Specific Identification of Striatonigral Medium Spiny Neurons. Front Syst Neurosci (2011) 1.15
HIV-related movement disorders: epidemiology, pathogenesis and management. CNS Drugs (2002) 1.13
Movement disorders and AIDS: a review. Parkinsonism Relat Disord (2004) 1.12
The dopamine response in the nucleus accumbens core-shell border differs from that in the core and shell during operant ethanol self-administration. Alcohol Clin Exp Res (2009) 1.09
Cerebrospinal fluid dopamine in HIV-1 infection. AIDS (1994) 1.09
Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol (2013) 1.08
Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav Immun (2011) 1.07
NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. J Neurosci Res (2005) 1.07
Comparison of dopamine D1 and D5 receptor knockout mice for cocaine locomotor sensitization. Psychopharmacology (Berl) (2008) 1.04
Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci (2000) 1.04
HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem (2000) 1.03
Crosstalk between components of the blood brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol (2001) 1.02
Dopaminergic neurotoxicity of HIV-1 gp120: reactive oxygen species as signaling intermediates. Brain Res (2009) 0.99
Molecular interactions of the type 1 human immunodeficiency virus transregulatory protein Tat with N-methyl-d-aspartate receptor subunits. Neuroscience (2005) 0.98
Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics (2012) 0.98
Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor. Neurotoxicology (2007) 0.97
Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine? Neuroscience (2013) 0.96
HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. J Neuroimmune Pharmacol (2012) 0.96
Cocaine sensitization: modulation by dopamine D2 receptors. Cereb Cortex (2002) 0.94
Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm (Vienna) (2010) 0.94
Recombinant human immunodeficiency virus-1 transactivator of transcription1-86 allosterically modulates dopamine transporter activity. Synapse (2011) 0.93
Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior. Brain Struct Funct (2013) 0.92
Modulation by dopamine D1-like receptors of synaptic transmission and NMDA receptors in rat nucleus accumbens is attenuated by the protein kinase C inhibitor Ro 32-0432. Neuropharmacology (1999) 0.92
Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions. J Neuroimmune Pharmacol (2013) 0.90
Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered. Curr HIV/AIDS Rep (2015) 0.90
Decreased homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin Neuropharmacol (2001) 0.90
Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J Neurosci Res (1991) 0.90
Loss of neuronal GSK3β reduces dendritic spine stability and attenuates excitatory synaptic transmission via β-catenin. Mol Psychiatry (2014) 0.89
HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner. J Neuroinflammation (2011) 0.88
Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats. Mol Neurodegener (2014) 0.87
HIV-1 protein Tat inhibits vesicular monoamine transporter-2 activity in rat striatum. Synapse (2012) 0.87
Regional and cell-type-specific effects of DAMGO on striatal D1 and D2 dopamine receptor-expressing medium-sized spiny neurons. ASN Neuro (2012) 0.86
Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry (1991) 0.86
Anxiety-like behavior of mice produced by conditional central expression of the HIV-1 regulatory protein, Tat. Psychopharmacology (Berl) (2013) 0.86
Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice. Proc Natl Acad Sci U S A (2012) 0.85
Eradication of human immunodeficiency virus from brain reservoirs. J Neurovirol (2014) 0.84
HIV Associated Neurocognitive Disorders. Infect Dis Rep (2013) 0.84
Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na⁺ influx, mitochondrial instability, and Ca²⁺ overload. J Neurosci (2014) 0.83
Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Arch Neurol (1991) 0.83
Morphine efficacy is altered in conditional HIV-1 Tat transgenic mice. Eur J Pharmacol (2012) 0.83
Role of dopamine D2 receptors in plasticity of stress-induced addictive behaviours. Nat Commun (2013) 0.83
Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV. J Neurol (2009) 0.83
Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport. J Neuroimmune Pharmacol (2015) 0.80
D1/NMDA receptors and concurrent methamphetamine+ HIV-1 Tat neurotoxicity. J Neuroimmune Pharmacol (2012) 0.79
Increased Sensitivity to Cocaine Self-Administration in HIV-1 Transgenic Rats is Associated with Changes in Striatal Dopamine Transporter Binding. J Neuroimmune Pharmacol (2015) 0.79
Activation of Direct and Indirect Pathway Medium Spiny Neurons Drives Distinct Brain-wide Responses. Neuron (2016) 0.78
Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention - A Comparison with Parkinson's Disease. Neuropsychol Rev (2015) 0.78
HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions. Curr Drug Targets (2015) 0.78
A short review on the relation between the dopamine transporter 10/10-repeat allele and ADHD: implications for HIV infection. Atten Defic Hyperact Disord (2014) 0.78
HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations. J Neurovirol (2016) 0.78
Loss of Plasticity in the D2-Accumbens Pallidal Pathway Promotes Cocaine Seeking. J Neurosci (2017) 0.78
Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals. J Neural Transm (Vienna) (2013) 0.78
The effects of HIV-1 regulatory TAT protein expression on brain reward function, response to psychostimulants and delay-dependent memory in mice. Neuropharmacology (2016) 0.77
HIV-1 Tat protein exposure potentiates ethanol reward and reinstates extinguished ethanol-conditioned place preference. Curr HIV Res (2014) 0.77
5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat. Brain Behav Immun (2016) 0.76
Central administration of angiotensin IV rapidly enhances novel object recognition among mice. Neuropharmacology (2013) 0.76
Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity. Curr HIV Res (2014) 0.76
Estrous cycle and HIV-1 Tat protein influence cocaine-conditioned place preference and induced locomotion of female mice. Curr HIV Res (2014) 0.76
Selective susceptibility of cultured striatal neurons to kainic acid. J Neurosci Res (1992) 0.76
Morphine Tolerance and Physical Dependence Are Altered in Conditional HIV-1 Tat Transgenic Mice. J Pharmacol Exp Ther (2015) 0.76
Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain. Neurobiol Dis (2016) 0.75
Dual Nitrergic/Cholinergic Control of Short-Term Plasticity of Corticostriatal Inputs to Striatal Projection Neurons. Front Cell Neurosci (2015) 0.75
Effects of HIV-1 Tat on enteric neuropathogenesis. J Neurosci (2014) 0.87
Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na⁺ influx, mitochondrial instability, and Ca²⁺ overload. J Neurosci (2014) 0.83
Oligodendrocytes Are Targets of HIV-1 Tat: NMDA and AMPA Receptor-Mediated Effects on Survival and Development. J Neurosci (2015) 0.78
Chronic low-level expression of HIV-1 Tat promotes a neurodegenerative phenotype with aging. Sci Rep (2017) 0.75